Free tool
FAERS Monitor: Belbuca
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 207932 or its brand name (Belbuca, Buprenorphine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
7,463
Serious
5,578
75% of reports
Hospitalization
1,117
Death reported
1,051
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dependence2,858
- overdose1,452
- death461
- drug ineffective426
- ill-defined disorder414
- nausea352
- pain330
- headache309
- foetal exposure during pregnancy306
- depression292
- product adhesion issue276
- maternal exposure during pregnancy273
- drug withdrawal syndrome neonatal271
- off label use268
- vomiting264
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 76 |
| 2005 | 14 |
| 2006 | 19 |
| 2007 | 4 |
| 2008 | 33 |
| 2009 | 21 |
| 2010 | 32 |
| 2011 | 25 |
| 2012 | 26 |
| 2013 | 155 |
| 2014 | 45 |
| 2015 | 69 |
| 2016 | 289 |
| 2017 | 138 |
| 2018 | 155 |
| 2019 | 222 |
| 2020 | 264 |
| 2021 | 199 |
| 2022 | 532 |
| 2023 | 3,285 |
| 2024 | 837 |
| 2025 | 711 |
| 2026 | 311 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,696 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| dependenceSignal | 2,858 | 155.0 | 150.4 | 415,322 |
| drug withdrawal syndrome neonatalSignal | 271 | 52.5 | 46.7 | 13,406 |
| product adhesion issueSignal | 276 | 21.9 | 19.5 | 5,460 |
| ill-defined disorderSignal | 414 | 19.3 | 17.6 | 7,150 |
| overdoseSignal | 1,452 | 19.1 | 18.2 | 24,965 |
| foetal exposure during pregnancySignal | 306 | 10.6 | 9.5 | 2,665 |
| maternal exposure during pregnancySignal | 273 | 8.7 | 7.7 | 1,843 |
| depressionSignal | 292 | 3.6 | 3.2 | 556 |
| vomiting | 264 | 1.6 | 1.4 | 57 |
| pain | 330 | 1.5 | 1.4 | 59 |
| death | 461 | 1.5 | 1.4 | 82 |
| headache | 309 | 1.4 | 1.2 | 34 |
| nausea | 352 | 1.3 | 1.1 | 18 |
| drug ineffective | 426 | 0.9 | 0.8 | 4 |
| off label use | 268 | 0.9 | 0.8 | 6 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.